The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.
Phase of Trial: Phase III
Latest Information Update: 01 Jan 2015
At a glance
- Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tumour necrosis factor alpha inhibitors
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms DREAM-TIME
- 30 Oct 2013 Preliminary results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 16 Feb 2012 Additional lead trial centre identified as reported by Netherlands Trial Register.
- 16 Feb 2012 Planned End Date changed from 31 Dec 2011 to 31 Mar 2013 as reported by Netherlands Trial Register.